Biotech · Private company

Dompé Farmaceutici S.p.A

Track this companyFree. Adds Dompé Farmaceutici S.p.A to your Dealase workspace and tells you when its record changes.

Clinical trials255 recruiting or active

Pipeline programs33From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline33

CenegerminPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
CenegerminPhase 3 · Non-Arteritic Anterior Ischemic Optic NeuropathyClinicalTrials.gov · fetched Nov 12, 2026
CenegerminPhase 3 · Persistent Corneal Epithelial DefectClinicalTrials.gov · fetched Nov 12, 2026
dexamethasone sodium phosphate (DSP) ophthalmic solutionPhase 3 · Atopic KeratoconjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
DFL24498Phase 3 · Atopic KeratoconjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
OxervatePhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
ReparixinPhase 3 · Islet Transplantation in Diabetes Mellitus Type 1ClinicalTrials.gov · fetched Nov 12, 2026
ReparixinPhase 3 · Pneumonia, ViralClinicalTrials.gov · fetched Nov 12, 2026
ReparixinPhase 3 · Infectious PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 3 · Atopic KeratoconjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 3 · Non-Arteritic Anterior Ischemic Optic NeuropathyClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 3 · Persistent Corneal Epithelial DefectClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 3 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
DFL24498Phase 2 · Dry Eye Disease (DED)ClinicalTrials.gov · fetched Nov 12, 2026
LadarixinPhase 2 · New-onset Type 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
LadarixinPhase 2 · Type I DiabetesClinicalTrials.gov · fetched Nov 12, 2026
LadarixinPhase 2 · Recent Onset type1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
ReparixinPhase 2 · FatigueClinicalTrials.gov · fetched Nov 12, 2026
Reparixin 600mgPhase 2 · Acute Respiratory Distress Syndrome, AdultClinicalTrials.gov · fetched Nov 12, 2026
Reparixin continuous infusionPhase 2 · Ischemia-Reperfusion InjuryClinicalTrials.gov · fetched Nov 12, 2026
reparixin intermittent infusionPhase 2 · Ischemia-Reperfusion InjuryClinicalTrials.gov · fetched Nov 12, 2026
RepertaxinPhase 2 · Ischemia-Reperfusion InjuryClinicalTrials.gov · fetched Nov 12, 2026
rhNGF 10 μg/mLPhase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
rhNGF 20 μg/mlPhase 2 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
rhNGF 20 μg/ml + vehiclePhase 2 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
rhNGF 5 μg/mLPhase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 2 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
VehiclePhase 2 · Dry Eye Disease (DED)ClinicalTrials.gov · fetched Nov 12, 2026
rhNGF 20μg/mLPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Cenegemin in the DEFENDO StudyNeurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
cenegermin-bkbjNeurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
observational studySjögren SyndromeClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)PHASE3 · RECRUITING · started Jul 1, 2026ClinicalTrials.gov NCT07453888 · fetched Nov 12, 2026
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDPHASE3 · RECRUITING · started Jun 2, 2026ClinicalTrials.gov NCT07519902 · fetched Nov 12, 2026
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseasePHASE2 · RECRUITING · started May 12, 2026ClinicalTrials.gov NCT07503886 · fetched Nov 12, 2026
An Efficacy and Safety Study of DFL24498 in the Treatment of AKCPHASE3 · RECRUITING · started Dec 1, 2025ClinicalTrials.gov NCT07395232 · fetched Nov 12, 2026
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry EyeTERMINATED · started May 9, 2024ClinicalTrials.gov NCT06411132 · fetched Nov 12, 2026
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.PHASE2 · COMPLETED · started Jan 22, 2024ClinicalTrials.gov NCT06244316 · fetched Nov 12, 2026
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)PHASE2 · RECRUITING · started Jul 24, 2023ClinicalTrials.gov NCT05835466 · fetched Nov 12, 2026
QST for Corneal Nerve FunctionNA · SUSPENDED · started May 16, 2023ClinicalTrials.gov NCT05758753 · fetched Nov 12, 2026
DEFENDO Long Term Follow-up Study in Stage 1 NK PatientsCOMPLETED · started Feb 1, 2023ClinicalTrials.gov NCT05552261 · fetched Nov 12, 2026
Add-on Reparixin in Adult Patients With ARDSPHASE2 · COMPLETED · started Dec 6, 2022ClinicalTrials.gov NCT05496868 · fetched Nov 12, 2026
Corneal Nerves After Treatment With CenegerminCOMPLETED · started May 23, 2022ClinicalTrials.gov NCT04627571 · fetched Nov 12, 2026
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired PneumoniaPHASE3 · TERMINATED · started Apr 27, 2022ClinicalTrials.gov NCT05254990 · fetched Nov 12, 2026
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerPHASE2 · WITHDRAWN · started Apr 19, 2022ClinicalTrials.gov NCT05212701 · fetched Nov 12, 2026
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye DiseasePHASE3 · COMPLETED · started Jan 27, 2022ClinicalTrials.gov NCT05136170 · fetched Nov 12, 2026
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)PHASE3 · COMPLETED · started Jan 19, 2022ClinicalTrials.gov NCT05133180 · fetched Nov 12, 2026
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 DiabetesPHASE2 · WITHDRAWN · started Sep 30, 2021ClinicalTrials.gov NCT05035368 · fetched Nov 12, 2026
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.PHASE3 · COMPLETED · started Feb 14, 2021ClinicalTrials.gov NCT04878055 · fetched Nov 12, 2026
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell FunctionPHASE2 · TERMINATED · started Jan 12, 2021ClinicalTrials.gov NCT04628481 · fetched Nov 12, 2026
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.PHASE2 · TERMINATED · started Dec 14, 2020ClinicalTrials.gov NCT04899271 · fetched Nov 12, 2026
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic KeratitisPHASE4 · COMPLETED · started Sep 9, 2020ClinicalTrials.gov NCT04485546 · fetched Nov 12, 2026
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry EyePHASE2 · COMPLETED · started Jun 10, 2019ClinicalTrials.gov NCT03982368 · fetched Nov 12, 2026
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy VolunteersPHASE1 · COMPLETED · started Mar 30, 2018ClinicalTrials.gov NCT03836859 · fetched Nov 12, 2026
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet TransplantationPHASE3 · COMPLETED · started Oct 1, 2012ClinicalTrials.gov NCT01817959 · fetched Nov 12, 2026
Reparixin in Prevention of Delayed Graft Function After Kidney TransplantationPHASE2 · COMPLETED · started Oct 1, 2005ClinicalTrials.gov NCT00248040 · fetched Nov 12, 2026
Repertaxin in Prevention of Primary Graft Dysfunction After Lung TransplantationPHASE2 · COMPLETED · started May 1, 2005ClinicalTrials.gov NCT00224406 · fetched Nov 12, 2026